No-reflow: A heterogeneous clinical phenomenon with multiple therapeutic strategies

Current Pharmaceutical Design

Volumn 12, Issue 29, 2006, Pages 3807-3815

  Galiuto, Leonarda ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Adenosine; Endothelin antagonists; Free radical; Myocardial blush grade (MBG); Myocardial perfusion; Post ischemic microcirculation

Indexed keywords

ABCIXIMAB; ADENOSINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DARUSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; FIBRINOGEN RECEPTOR ANTAGONIST; GALLOPAMIL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NICORANDIL; NIFEDIPINE; PAPAVERINE; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; ROVELIZUMAB; URAPIDIL; VERAPAMIL;

BLOOD CLOT LYSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART VENTRICLE REMODELING; HUMAN; MICROVASCULATURE; NO REFLOW PHENOMENON; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR PATENCY;

ADENOSINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CORONARY CIRCULATION; CORONARY VESSELS; HUMANS; MAGNETIC RESONANCE IMAGING; MICROCIRCULATION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NICORANDIL; POTASSIUM CHANNELS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VASCULAR PATENCY;

EID: 33749840457     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206778559803     Document Type: Review

References (67)

1. Krug A, Du Mesnil de Rochemont, Korb G. Blood supply of the myocardium after temporary coronary occlusion. Circ Res 1966; 19: 57-62.
2. Kloner RA, Rude RE, Carlson N, Maroko PR, DeBoer LW, Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation 1980; 62: 945-952.
3. Kloner RA, Ganote CE, Jenning RB. The "no-reflow" phenomenon after temporary coronary occlusion in dogs. J Clin Invest 1974; 54: 1496-1508.
4. Galiuto L. Optimal Therapeutic Strategy in the Setting of Post-Infarct No-Reflow: The Need for a Pathogenetic Classification. Heart 2004; 90: 123-125.
5. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical Implications of the "No-Reflow" Phenomenon. A Predictor of Complications and Left Ventricular Remodeling in Reperfused Anterior Wall Myocardial Infarction. Circulation 1996; 93: 223-228.
6. Tillmanns H, Steinhausen M, Leinberger H. Hemodynamics of the coronary microcirculation during myocardial ischemia. Circulation 1981; 64(Suppl IV): 40.
7. Vanhaecke J, Flameng W, Borgers M, Jang IK, Van de Werf F, De Geest H. Evidence for decreased coronary flow reserve in viable postischemic myocardium. Circ Res 1990; 67: 1201-1210.
8. Quillen JE, Selke FW, Brooks LA, Harrison DG. Ischemia-reperfusion impairs endothelium-dependent relaxation of coronary microvessels but does not affect large arteries. Circulation 1990; 82: 586-594.
9. Bolli R, Triana F, Jeroudi MO. Prolonged impairment of coronary vasodilation after reversible ischemia. Evidence for microvascular stunning. Circ Res 1990; 67: 332-343.
10. Hellstrom RH. The injury-spasm [ischemia-induced hemostatic vasoconstrictive] and vascular autoregulatory hypothesis of ischemic disease. Resistance vessel-spasm hypothesis of ischemic disease. Am J Cardiol 1982; 49: 802-810.
11. Manciet LH, Poole DC, Mcdonagh PF. Microvascular compression during myocardial ischemia: mechanistic basis for no-reflow phenomenon. Am J Physiol 1994; 266: H1541-1550.
12. Engler RE, Schmid-Schönbheim GW, Pavalee RS. Leukocyte capillary plugging in myocardial ischemia-reperfusion in the dog. Am J Pathol 1983; 111: 98-111.
13. Wilson RF, Laxson DD, Lesser JR, White CW. Intense Microvascular Constriction After Angioplasty of Acute Thrombotic Coronary Arterial Lesions. The Lancet 1989; 1(8642): 807-811.
14. Ambrosio G, Weisman HF, Mannisi JA, Becker LC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation 1989; 80: 1846-1861.
15. Jeremy RW, Links JM, Becker LC. Progressive failure of coronary flow during reperfusion of myocardial infarction: documentation of the no reflow phenomenon with Positron Emission Tomography. J Am Coll Cardiol 1990; 16: 695-704.
16. Galiuto L, DeMaria AN, May-Newman K, del Balzo U, Ohmori K, Bhargava V, et al. Evaluation of Dynamic Changes in Microvascular Flow During Ischemia-Reperfusion by Myocardial Contrast Echocardiography. J Am Coll Cardiol 1998; 32: 1096-1101.
17. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D, et al. Temporal Evolution and Functional Outcome of No-Reflow: Sustained and Spontaneously Reversible Patterns Following Successful Coronary Recanalization. Heart 2003; 89: 731-737.
18. The Thrombolysis in Myocardial Infarction [TIMI] trial, phase I findings: TIMI Study Group. N Engl J Med 1985; 312: 932-936.
19. Ito H, Okamura A, Iwakura Y, Masuyama T, Hori M, Takiuchi S, et al. Myocardial Perfusion Patterns Related to Thrombolysis in Myocardial Infarction Perfusion Grades after Coronary Angioplasty in Patients with Acute Anterior Wall Myocardial Infarction. Circulation 1996; 93: 1993-1999.
20. van't Hof AWJ, Liem A, Suryapranata H, Hoorntje Jan CA, de Boer M, Zijlstra F, el al. Angiographic assessment of Myocardial Reperfusion in Patients Treated with Primary Angioplasty for Acute Myocardial Infarction: Myocardial Blush Grade: Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302-2306.
21. Henriques JPS, Zijlstra F, van't Hof AWJ, de Boer M, Dambrink J E, Gosselink M, et al. Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade. Circulation 2003; 107: 2115-2119.
22. Santoro GM, Valenti R, Buonamici P, Bolognese L, Cerisano G. Relation between ST-segment Changes and Myocardial Perfusion Evaluated by Myocardial Contrast Echocardiography in Petients with Acute Myocardial Infarction Treated with Direct Angioplasty. Am J Cardiol 1998; 82: 932-937.
23. Iwakura K, Ito H, Nishikawa N, Kiraoka K, Sugimoto K, Higashino Y, et al. Early Temporal Changes in Coronary Flow Velocity Patterns in Patients with Acute Myocardial Infarction Demonstrating the "no-reflow" Phenomenon. Am J cardiol 1999; 84: 415-419.
24. Greaves K, Dixon SR, Fejka M, O'Neill WW, Redwood SR, Marber Senior R. Myocardial Contrast Echocardiography is Superior to Other Known Modalities for Assessing Myocardial Reperfusion After Acute Myocardial Infarction. Heart 2003; 89: 139-144.
25. Saeed M, Wendland MF, Takehara Y, Masui T, Higgins CB. Reperfusion and Irreversible Myocardial Injury: Identification with a Nonionic MR Imaging Contrast Medium. Radiology 1992; 182: 675-683.
26. Ryan T, Tarver RD, Duerk JL, Sawada SG, Hollenkamp NC. Distinguishing Viable from Infarcted Myocardium after Experimental Ischemia and Reperfusion by Using Nuclear Magnetic Resonance Imaging. J Am Coll Cardiol 1990; 15: 1355-1364.
27. Jeremy RW, Links JM, Becker LC. Progressive Failure of Coronary Flow During Reperfusion of Myocardial Infarction: Documentation of the No-reflow Phenomenon with Positron Emission Tomography. J Am Coll Cardiol 1990; 16: 695-704.
28. Knabb RM, Bergmann SR, Fox KAA, Sobel BE. The Temporal Pattern of Recovery of Myocardial Perfusion and Metabolism Delineated by Positron Emission Tomography After Coronary Thrombolysis. J Nucl Med 1987; 28: 1563-1570.
29. Sakuma T, Hayashi Y, Sumii K, Imazu M, Yamakido M. Prediction of Short- and Interinediate-Term Prognoses of Patients with Acute Myocardial Infarction Using Myocardial Contrast Echocardiography One Day After Recanalization. J Am Coll Cardiol 1998; 32: 890-7.
30. De Luca G, van't Hof AWJ, de Boer MJ, Hoorntje J, Gosselink M, Dambrink Jan-Henk E, et al. Impaired Myocardial Perfusion Is a Major Explanation of the Poor Outcome Observed in Patients Undergoing Primary Angioplasty for ST-Segment-Elevation Myocardial Infarction and Signs of Heart Failure. Circulation 2004; 109: 958-961.
31. Bolognese L, Carrabba N, Parodi G, Santoro GM, Buonamici P, Cerisano G, et al. Impact of Microvascular Dysfunction on Left Ventricular Remodeling and Long-Term Clinical Outcome After Primary Coronary Angioplasty for Acute Myocardial Infarction. Circulation 2004; 109: 1121-1126.
32. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic Significance of Microvascular Obstruction by Magnetic Resonance Imaging in Patients With Acute Myocardial Infarction. Circulation 1998; 97: 765-772.
33. Tillmanns H, Neumann FJ, Parekh N, Dorigo O, Tiefenbacher C, Zimmermann R, et al. Pharmacologic effects on coronary microvessels during myocardial ischentia. Eur Heart J 1990; 11: 10-15.
34. Villari B, Ambrosio G, Golino P, Ragni M, Focaccio A, Tritto L, et al. The effects of calcium channel antagonist treatment and oxygen radical scavenging on infarct size and the no-reflow phenomenon in reperfused hearts. Am Heart J 1993; 125: 11-23.
35. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial Effect of Intracoronary Verapamil on Microvascular and Myocardial Salvage in Patients With Acute Myocardial Infarction. J Am Coll Cardiol 1997; 30: 1193-1199.
36. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and Treatment of "No-Reflow" After Percutaneous Coronary Intervention. Circulation 1994; 89: 2514-2518.
37. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989; 63: 18-24J.
38. Taniyama Y, Ito H, Iwakura K, Takiuchi S, Masuyama A, Fujii K. Effects of intracoronary injection of verapamil and nicorandil on microcirculation and left ventricular function in patients with reperfused myocardial infarction. Circulation 1995; 92: 1-77.
39. Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 1987; 76: 1135-1145.
40. Berne RM. The role of adenosine in the regulation of coronary blood flow. Circ Res 1980; 47: 807-13.
41. Cronstein BN, Levin RI, Belanoff J, Weissman G, Hirschorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986; 78: 760-70.
42. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000: 101(18): 2154-9.
43. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine [AMISTAD] trial. J Am Coll Cardiol. 1999 Nov 15; 34(6): 1711-20.
44. Ishihara M, Sato H, Tateishi H, Kawagoe T, Shimatani Y, Kurisu S, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996; 132: 959-963.
45. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988: 332: 411-415.
46. Stewart DJ, George K, Costello K, Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol 1991; 18: 38-43.
47. Velasco CE, Turner M, Inagami T, Atkinson J.B, Virmani R, Jackson E.K, et al. Reperfusion enhances the local release of endothelin after regional myocardial ischemia. Am heart J 1994; 128: 441-451.
48. Pernow J, Wang QD. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res 1997; 33: 518-526.
49. Wang QD, Li XS, Lundberg JM, Pernow J. Protective effect of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovascular Research 1995; 29: 805-812.
50. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993; 27: 1613-1618.
51. Galiuto L, DeMaria AN, del Balzo U, May-Newman K, Wolf PL, Kirchengast M, et al. Ischemia-Reperfusion Injury at the Microvascular Level: Treatment by Endothelin-A Selective Antagonist and Evaluation by Myocardial Contrast Echocardiography. Circulation 2000; 102: 3111-3116.
52. Gregorini L, Marco J, Kozakova M, Palombo C, Anguissola GB, Marco I, et al. α- Adrenergic Blockade Improves Recovery of Myocardial Perfusion and Function After Coronary Stenting in Patients with Acute Myocardial Infarction. Circulation 1999; 99: 482-490.
53. Topol EJ, Yadav JS. Recognition of the Importance of Embolization in Atherosclerosclerotic Vascular Disease. Circulation 2000; 101: 570-580.
54. Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, Overlie PA, et al., on behalf of the Primary Angioplasty in Myocardial Infarction [PAMI] Investigators. Improved Short-Term Outcomes of Primary Coronary Stenting Compared to Primary Balloon Angioplasty in Acute Myocardial Infarction at Experienced Centers: the PAMI study Group Experience. J Intervent Cardiol 1999; 12: 101-108.
55. Limbruno U, Micheli A, De Carlo M, Amoroso G, Rossini R, Palagi C, et al. Mechanical Prevention of Distal Embolization During Primary Angioplasty. Safety, Feasibility, and Impact on Myocardial Reperfusion. Circulation 2003; 108: 171-176.
56. Napodano M, Pasquetto G, Saccà S, Cernetti C, Scarabeo V, Pascotto P, et al. Intracoronary Thrombectomy Improves Myocardial Reperfusion in Patients Undergoing Direct Angioplasty for Acute Myocardial Infarction. J Am Coll Cardiol 2003; 42: 1395-1402.
57. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of Glycoprotein IIb/IIIa Receptor Blockade on Recovery of Coronary Flow and Left Ventricular Function After the Placement of Coronary Artery Stents in Acute Myocardial Infarction. Circulation 1998; 98: 2695-2701.
58. De Lemos JA, Antman EM, Gigson M, Mc Cabe CH, Giugliano RP, Murphy SA, et al. Abciximab Improves Both Epicardial Flow and Myocardial Reperfusion in ST-Elevation Myocardial Infarction. Observations from the TIMI 14 Trial. Circulation 2000; 101: 239-243.
59. Petronio AS, Rovai D, Musumeci G, Baglini R, Nardi C, Limbrano U, et al. Effects of Abciximab on Microvascular Integrity and Left Ventricular Functional Recovery in Patients With Acute Infarction Treated by Primary Coronary Angioplasty. Eur Heart J 2003; 24: 67-76.
60. Faxon DP, Gibbons RJ, Chronos NAF, Gurbel PA, Sheehan F for the HALT-MI Investigators. The Effects of Blockade ofthe CD 11/CD 18 Integrin Receptor on Infarct Size in Patients with Acute Myocardial Infarction Treated With Direct Angioplasty: The Results of the HALT-MI Study. J Am Coll Cardiol 2002; 40: 1190-204i.
61. Mc Cord JM. Oxygen-derived free radicals in post-ischemic tissue injury. N Engl J Med 1985; 312: 159-163.
62. Ambrosio G, Becker LC, Hutchins GM, Weisman HF, Weisfeldt ML. Reduction in experimental infarct size by recombinant human superoxide dismutase: Insights into the pathophysiology of reperfusion injury. Circulation 1986; 74: 1424-1433.
63. Gallagher KP, Buda AJ, Pace D, Gerren RA, Shlafer M. Failure of superoxide dismutase and catalase to alter size of infarction in conscious dogs after 3 hours of occlusion followed by reperfusion. Circulation 1986; 73: 1065-1076.
64. Dauber IM, Lesnefsky EJ, VanBenthuysen KM, Weil JV, Horwitz LD. Reactive oxygen metabolite scavengers decrease functional coronary microvascular injury due to ischemia-reperfusion. Am J Physiol, 1991; 260: H42-H49.
65. Mehta JL, Nichols WW, Donnelly WH, Lawson DL, Thompson L, Ter Riet M, et al. Protection by superoxide dismutase from myocardial dysfunction and attenuation of vasodilator reserve after coronary occlusion and reperfusion in dog. Circ Res 1989; 65: 1283-1295.
66. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, et al. Association Between Hyperglycemia and the No-Reflow Phenomenon in Patients With Acute Myocardial Infarction. J Am Coll Cardiol 2003: 41: 1-7.
67. ATP Channel Opening is an Endogenous Mechanism of Protection Against the No-Reflow Phenomenon but its Function is Compromised by Hypercholesterolemia. J Am Coll Cardiol 2002; 40: 1339-1346.